Search ACTG publications from 1/1/2006 to current.


Filter results by

Found 26 results
Filters: First Letter Of Title is D  [Clear All Filters]
Found 26 results.
Skip Alphabet Links A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  


Kelesidis T, Yang OO, Kendall MA, Hodis HN, Currier JS. "Dysfunctional HDL and progression of atherosclerosis in HIV-1-infected and -uninfected adults." Lipids Health Dis. 2013;12:23.
Koelsch KK, Liu L, Haubrich R, et al. "Dynamics of total, linear nonintegrated, and integrated HIV-1 DNA in vivo and in vitro." J. Infect. Dis.. 2008;197(3):411-9.
Funderburg NT, Andrade A, Chan ES, et al. "Dynamics of immune reconstitution and activation markers in HIV+ treatment-naïve patients treated with raltegravir, tenofovir disoproxil fumarate and emtricitabine." PLoS ONE. 2013;8(12):e83514.
Wang R, Bosch RJ, Benson CA, Lederman MM. "Drug-resistant virus has reduced ability to induce immune activation." J. Acquir. Immune Defic. Syndr.. 2012;61(4):e60-3.
Wallis CL, Aga E, Ribaudo H, et al. "Drug susceptibility and resistance mutations after first-line failure in resource limited settings." Clin. Infect. Dis.. 2014;59(5):706-15.
Schnitzer ME, Lok JJ, Bosch RJ. "Double robust and efficient estimation of a prognostic model for events in the presence of dependent censoring." Biostatistics. 2016;17(1):165-77.
Bednar MM, Hauser BM, Zhou S, et al. "Diversity and Tropism of HIV-1 Rebound Virus Populations in Plasma Level After Treatment Discontinuation." J. Infect. Dis.. 2016;214(3):403-7.
Rouabhia M, Semlali A, Chandra J, Mukherjee P, Chmielewski W, Ghannoum MA. "Disruption of the ECM33 gene in Candida albicans prevents biofilm formation, engineered human oral mucosa tissue damage and gingival cell necrosis/apoptosis." Mediators Inflamm.. 2012;2012:398207.
Sun J, Nagaraj HN, Reynolds NR. "Discrete stochastic models for compliance analysis based on an AIDS Clinical Trial Group (ACTG) study." Biom J. 2007;49(5):731-41.
Zhang X, Tierney C, Albrecht M, et al. "Discordant associations between SLCO1B1 521T→C and plasma levels of ritonavir-boosted protease inhibitors in AIDS clinical trials group study A5146." Ther Drug Monit. 2013;35(2):209-16.
Snoeck J, Kantor R, Shafer RW, et al. "Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent." Antimicrob. Agents Chemother.. 2006;50(2):694-701.
Johs NA, Wu K, Tassiopoulos K, et al. "Disability Among Middle-Aged and Older Persons With Human Immunodeficiency Virus Infection." Clin. Infect. Dis.. 2017;65(1):83-91.
Henrich TJ, Lewine NRP, Lee S-H, et al. "Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists." Antimicrob. Agents Chemother.. 2012;56(4):1931-5.
Katsounas A, Frank AC, Lempicki RA, Polis MA, Asmuth DM, Kottilil S. "Differential Specificity of Interferon-alpha Inducible Gene Expression in Association with Human Immunodeficiency Virus and Hepatitis C Virus Levels and Declines in vivo." J AIDS Clin Res. 2015;6(1).
Grant PM, Kitch D, McComsey GA, Tierney C, Ha B, Brown TT. "Differential skeletal impact of tenofovir disoproxil fumarate in young versus old HIV-infected adults." HIV Clin Trials. 2015;16(2):66-71.
Chan ES, Landay AL, Brown TT, et al. "Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir." AIDS. 2016;30(13):2091-7.
Firnhaber C, Smeaton LM, Grinsztejn B, et al. "Differences in antiretroviral safety and efficacy by sex in a multinational randomized clinical trial." HIV Clin Trials. 2015;16(3):89-99.
Goicoechea M, Smith DM, Liu L, et al. "Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA." J. Infect. Dis.. 2006;194(1):29-37.
C Hare B, Mellors J, Krambrink A, et al. "Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy." Clin. Infect. Dis.. 2008;47(3):421-4.
Seaman WT, Andrews E, Couch M, et al. "Detection and quantitation of HPV in genital and oral tissues and fluids by real time PCR." Virol. J.. 2010;7:194.
Zheng L, Rosenkranz SL, Taiwo B, Para MF, Eron JJ, Hughes MD. "The design of single-arm clinical trials of combination antiretroviral regimens for treatment-naive HIV-infected patients." AIDS Res. Hum. Retroviruses. 2013;29(4):652-7.
Ribaudo HJ, Kuritzkes DR, Schackman BR, Acosta EP, Shikuma CM, Gulick RM. "Design issues in initial HIV-treatment trials: focus on ACTG A5095." Antivir. Ther. (Lond.). 2006;11(6):751-60.
Demeter LM, A Mukherjee L, DiFrancesco R, et al. "The design and implementation of A5146, a prospective trial assessing the utility of therapeutic drug monitoring using an inhibitory quotient in antiretroviral-experienced HIV-infected patients." HIV Clin Trials. 2008;9(1):61-72.
Luque AE, Cohn SE, Park J-G, et al. "Depot medroxyprogesterone acetate in combination with a twice-daily lopinavir-ritonavir-based regimen in HIV-infected women showed effective contraception and a lack of clinically significant interactions, with good safety and tolerability: results of the." Antimicrob. Agents Chemother.. 2015;59(4):2094-101.
Cohn SE, Park J-G, Watts DH, et al. "Depo-medroxyprogesterone in women on antiretroviral therapy: effective contraception and lack of clinically significant interactions." Clin. Pharmacol. Ther.. 2007;81(2):222-7.
Tenorio AR, Jiang H, Zheng Y, et al. "Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115." AIDS Res. Hum. Retroviruses. 2009;25(2):135-9.